Supriya Lifescience: Balasaheb Sawant Re-appointed Whole Time Director
Supriya Lifescience Limited announced that Mr. Balasaheb Sawant has been re-appointed as Whole Time Director and Key Managerial Personnel for a three-year term from May 26, 2026, to May 25, 2029. The re-appointment was passed as a special resolution via postal ballot with an overwhelming majority. The voting concluded on August 21, 2026.
The re-appointment of an existing director is a routine corporate governance event and is unlikely to have a significant immediate impact on the company's stock price or operations.
The re-appointment of a key managerial personnel with a substantial majority indicates strong support from shareholders, which is a positive development for the company's stability and governance.
Supriya Lifescience Limited has announced the voting results and the Scrutinizer's Report for a postal ballot conducted through remote e-voting. In continuation of their letter dated July 21, 2026, the company submitted the voting results as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The following resolution was passed with the requisite majority on August 21, 2026:
* Re-appointment of Mr. Balasaheb Sawant (DIN: 07743507) as Whole Time Director and Key Managerial Personnel for a term of three consecutive years, from May 26, 2026, to May 25, 2029. This was passed as a Special Resolution.
The company also informed that the notice for the postal ballot was issued on May 22, 2026. The remote e-voting period commenced on July 23, 2026, at 9:00 a.m. IST and concluded on August 21, 2026, at 5:00 p.m. IST. Out of 5,82,81,483 votes cast, 5,81,00,796 votes (99.69%) were in favor of the resolution, and 1,80,687 votes (0.31%) were against it.
This information is also available on the company's website and the NSDL e-voting website.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.